Literature DB >> 6982394

Biochemical and cell cycle perturbations in methotrexate-treated cells.

I W Taylor, P Slowiaczek, P R Francis, M H Tattersall.   

Abstract

The effects of methotrexate (MTX) in the presence or absence of exogenous thymidine (dThd, 10(-5) M) or hypoxanthine (Hx, 10(-4) M) on cell cycle kinetics and deoxyribonucleoside triphosphate pools (dNTP) were studied in cultured human leukemic T-cells (CCRF-CEM). MTX cytotoxicity was found to increase linearly with drug dose for MTX concentrations between 10(-9) M and 10(-7) M. No further increase in cytoxicity was observed with much higher MTX concentrations (10(-7) M-10(-4) M). A similar dose-response relationship was found for both MTX-induced inhibition of DNA synthesis and changes in dTTP and dGTP pools but not for either MTX-induced inhibition of purine synthesis or changes in dATP and dCTP pools. Exogenous dThd reduced MTX cytotoxicity, at all MTX concentrations examined, but Hx reduced cytotoxicity only at MTX concentrations less than 6 X 10(-8) M and potentiated toxicity with higher MTX concentrations. This potentiation of cytotoxicity was accompanied by substantial elevation of dATP pools. In all instances where dThd or Hx reduced MTX cytotoxicity, a concomitant increase in both dTTP and dGTP levels and in the rate of DNA synthesis was observed. These results suggest a close correlation between MTX-induced alterations of dNTP and inhibition of DNA synthesis and subsequent MTX cytotoxicity. The possible modulation of MTX cytotoxicity by purines is discussed.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6982394

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  5 in total

1.  Melanin synthesis and the action of L-dopa and 3,4-dihydroxybenzylamine in human melanoma cells.

Authors:  E P Kable; P G Parsons
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 2.  Tomudex (ZD1694): from concept to care, a programme in rational drug discovery.

Authors:  A L Jackman; F T Boyle; K R Harrap
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

3.  Enhanced cytotoxicity with methotrexate in conjunction with hypoxanthine in L1210 cells in culture.

Authors:  C R Fairchild; J Maybaum; J A Straw
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

4.  Methotrexate cytotoxicity as related to irreversible S phase arrest in mouse L1210 leukemia cells.

Authors:  M Tsurusawa; M Niwa; N Katano; T Fujimoto
Journal:  Jpn J Cancer Res       Date:  1990-01

5.  Preclinical cellular pharmacology of LY231514 (MTA): a comparison with methotrexate, LY309887 and raltitrexed for their effects on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells.

Authors:  V J Chen; J R Bewley; S L Andis; R M Schultz; P W Iversen; C Shih; L G Mendelsohn; D E Seitz; J L Tonkinson
Journal:  Br J Cancer       Date:  1998       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.